{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:24:56Z","timestamp":1786980296273,"version":"build-2736575974"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T00:00:00Z","timestamp":1701043200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T00:00:00Z","timestamp":1701043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["5R01CA222246-04"],"award-info":[{"award-number":["5R01CA222246-04"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s00520-023-08170-y","type":"journal-article","created":{"date-parts":[[2023,11,26]],"date-time":"2023-11-26T22:01:42Z","timestamp":1701036102000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The lived experience of patients with breast cancer on adjuvant endocrine therapy: side effects and coping strategies during the first year of medication initiation"],"prefix":"10.1007","volume":"31","author":[{"given":"Sameh","family":"Gomaa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AnaMaria","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Slamon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Lapitan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ginah","family":"Nightingale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne M.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuang-Yi","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,27]]},"reference":[{"issue":"3","key":"8170_CR1","doi-asserted-by":"crossref","first-page":"438","DOI":"10.4103\/ijc.IJC_83_21","volume":"59","author":"MA Bashar","year":"2022","unstructured":"Bashar MA, Begam N (2022) Breast cancer surpasses lung cancer as the most commonly diagnosed cancer worldwide. Indian J Cancer 59(3):438\u2013439","journal-title":"Indian J Cancer"},{"key":"8170_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","volume":"66","author":"M Arnold","year":"2022","unstructured":"Arnold M et al (2022) Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast 66:15\u201323","journal-title":"Breast"},{"issue":"6","key":"8170_CR3","first-page":"524","volume":"72","author":"AN Giaquinto","year":"2022","unstructured":"Giaquinto AN et al (2022) Breast cancer statistics, 2022. CA: A Cancer J Clin 72(6):524\u2013541","journal-title":"CA: A Cancer J Clin"},{"issue":"17","key":"8170_CR4","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1056\/NEJMoa050518","volume":"353","author":"DA Berry","year":"2005","unstructured":"Berry DA et al (2005) Effect of Screening and Adjuvant Therapy on Mortality from Breast Cancer. N Engl J Med 353(17):1784\u20131792","journal-title":"N Engl J Med"},{"issue":"9453","key":"8170_CR5","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S0140-6736(04)17666-6","volume":"365","author":"A Howell","year":"2005","unstructured":"Howell A et al (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years\u2019 adjuvant treatment for breast cancer. Lancet 365(9453):60\u201362","journal-title":"Lancet"},{"issue":"9793","key":"8170_CR6","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","volume":"378","author":"C Davies","year":"2011","unstructured":"Davies C et al (2011) Early Breast Cancer Trialists\u2032 Collaborative Group (EBCTCG) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378(9793):771\u201384","journal-title":"Lancet"},{"key":"8170_CR7","doi-asserted-by":"crossref","unstructured":"Early Breast Cancer Trialists' Collaborative G (1998) Tamoxifen for early breast cancer : an overview of the randomized trials. Lancet 351: p. 1451\u20131467","DOI":"10.1016\/S0140-6736(97)11423-4"},{"key":"8170_CR8","doi-asserted-by":"crossref","unstructured":"Burstein HJ et al (2010) American society of clinical oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor\u2013positive breast cancer. J Clin Oncol 28(23):3784\u20133796","DOI":"10.1200\/JCO.2009.26.3756"},{"issue":"2","key":"8170_CR9","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s10549-012-2114-5","volume":"134","author":"CC Murphy","year":"2012","unstructured":"Murphy CC et al (2012) Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat 134(2):459\u2013478","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"8170_CR10","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1200\/JCO.2003.07.071","volume":"21","author":"AH Partridge","year":"2003","unstructured":"Partridge AH, Wang PS, Winer EP, Avorn J (2003) Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 21(4):602\u2013606","journal-title":"J Clin Oncol"},{"issue":"4","key":"8170_CR11","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1200\/JCO.2007.11.5451","volume":"26","author":"AH Partridge","year":"2008","unstructured":"Partridge AH et al (2008) Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 26(4):556\u2013562","journal-title":"J Clin Oncol"},{"issue":"1","key":"8170_CR12","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.pec.2004.10.005","volume":"59","author":"EA Grunfeld","year":"2005","unstructured":"Grunfeld EA, Hunter MS, Sikka P, Mittal S (2005) Adherence beliefs among breast cancer patients taking tamoxifen. Patient Educ Couns 59(1):97\u2013102","journal-title":"Patient Educ Couns"},{"issue":"2","key":"8170_CR13","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1200\/JCO.2001.19.2.322","volume":"19","author":"S Demissie","year":"2001","unstructured":"Demissie S, Silliman RA, Lash TL (2001) Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. J Clin Oncol 19(2):322\u2013328","journal-title":"J Clin Oncol"},{"issue":"2","key":"8170_CR14","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s10549-006-9193-0","volume":"99","author":"TL Lash","year":"2006","unstructured":"Lash TL et al (2006) Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat 99(2):215\u2013220","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"8170_CR15","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1097\/01.mlr.0000257193.10760.7f","volume":"45","author":"KL Kahn","year":"2007","unstructured":"Kahn KL et al (2007) Patient centered experiences in breast cancer: predicting long-term adherence to tamoxifen use. Med Care 45(5):431\u2013439","journal-title":"Med Care"},{"issue":"3","key":"8170_CR16","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s10549-011-1668-y","volume":"129","author":"U G\u00fcth","year":"2011","unstructured":"G\u00fcth U et al (2011) Drug switch because of treatment-related adverse side effects in endocrine adjuvant breast cancer therapy: how often and how often does it work? Breast Cancer Res Treat 129(3):799\u2013807","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"8170_CR17","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s10549-007-9548-1","volume":"107","author":"D Cella","year":"2008","unstructured":"Cella D, Fallowfield LJ, Fallowfield LJ (2008) Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy. Breast Cancer Res Treat 107(2):167\u2013180","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"8170_CR18","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1002\/pon.1593","volume":"19","author":"I Pellegrini","year":"2010","unstructured":"Pellegrini I et al (2010) Women\u2019s perceptions and experience of adjuvant tamoxifen therapy account for their adherence: breast cancer patients\u2019 point of view. Psychooncology 19(5):472\u2013479","journal-title":"Psychooncology"},{"issue":"9","key":"8170_CR19","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1200\/JCO.2011.38.0261","volume":"30","author":"NL Henry","year":"2012","unstructured":"Henry NL et al (2012) Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol\u202f: Off J Am Soc Clin Oncol 30(9):936\u2013942","journal-title":"J Clin Oncol : Off J Am Soc Clin Oncol"},{"issue":"2","key":"8170_CR20","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3816\/CBC.2008.n.016","volume":"8","author":"MC Kirk","year":"2008","unstructured":"Kirk MC, Hudis CA (2008) Insight into Barriers Against Optimal Adherence to Oral Hormonal Therapy in Women with Breast Cancer. Clin Breast Cancer 8(2):155\u2013161","journal-title":"Clin Breast Cancer"},{"issue":"3","key":"8170_CR21","doi-asserted-by":"publisher","first-page":"104","DOI":"10.35680\/2372-0247.1173","volume":"4","author":"K-Y Wen","year":"2017","unstructured":"Wen K-Y, Smith R, Padmanabhan A, Goldstein L (2017) Patient experience of taking adjuvant endocrine therapy for breast cancer: a tough pill to swallow. Patient Experience J 4(3):104\u2013114","journal-title":"Patient Experience J"},{"issue":"2","key":"8170_CR22","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s10549-014-2961-3","volume":"145","author":"AL Stanton","year":"2014","unstructured":"Stanton AL, Petrie KJ, Partridge AH (2014) Contributors to nonadherence and nonpersistence with endocrine therapy in breast cancer survivors recruited from an online research registry. Breast Cancer Res Treat 145(2):525\u2013534","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"8170_CR23","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s10549-012-2066-9","volume":"134","author":"A Neugut","year":"2012","unstructured":"Neugut A et al (2012) Non-initiation of adjuvant hormonal therapy in women with hormone receptor-positive breast cancer: The Breast Cancer Quality of Care Study (BQUAL). Breast Cancer Res Treat 134(1):419\u2013428","journal-title":"Breast Cancer Res Treat"},{"key":"8170_CR24","unstructured":"Rani NS, Abd Wahab MS, Zulkifly HH, SH (2021) Mohamad, Factors associated with disease progression among hormone receptor-positive breast cancer patients treated with endocrine therapy: A 5-year cross-sectional, retrospective follow-up study. J Appl Pharm Sci 11(1): p. 072\u2013077"},{"issue":"1","key":"8170_CR25","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s10549-013-2422-4","volume":"138","author":"L Huiart","year":"2013","unstructured":"Huiart L, Ferdynus C, Giorgi R (2013) A meta-regression analysis of the available data on adherence to adjuvant hormonal therapy in breast cancer: summarizing the data for clinicians. Breast Cancer Res Treat 138(1):325\u2013328","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"8170_CR26","doi-asserted-by":"publisher","first-page":"e2225345","DOI":"10.1001\/jamanetworkopen.2022.25345","volume":"5","author":"N Sood","year":"2022","unstructured":"Sood N et al (2022) Association of Endocrine Therapy Initiation Timeliness With Adherence and Continuation in Low-Income Women With Breast Cancer. JAMA Netw Open 5(8):e2225345\u2013e2225345","journal-title":"JAMA Netw Open"},{"key":"8170_CR27","unstructured":"Strauss A. Corbin JM, Basics of Qualitative Research: Techniques and Procedures for Developing Grounded Theory. 1998: SAGE Publications"},{"key":"8170_CR28","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1007\/s00520-017-3613-z","volume":"25","author":"D Beckw\u00e9e","year":"2017","unstructured":"Beckw\u00e9e D, Leysen L, Meuwis K, Adriaenssens N (2017) Prevalence of aromatase inhibitor-induced arthralgia in breast cancer: a systematic review and meta-analysis. Support Care Cancer 25:1673\u20131686","journal-title":"Support Care Cancer"},{"key":"8170_CR29","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s10549-010-0757-7","volume":"120","author":"OS Din","year":"2010","unstructured":"Din OS, Dodwell D, Wakefield RJ, Coleman RE (2010) Aromatase inhibitor-induced arthralgia in early breast cancer: what do we know and how can we find out more? Breast Cancer Res Treat 120:525\u2013538","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"8170_CR30","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3747\/co.v17i1.473","volume":"17","author":"L Kligman","year":"2010","unstructured":"Kligman L, Younus J (2010) Management of hot flashes in women with breast cancer. Curr Oncol 17(1):81\u201386","journal-title":"Curr Oncol"},{"issue":"2","key":"8170_CR31","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1097\/GME.0b013e31826560da","volume":"20","author":"J Baumgart","year":"2013","unstructured":"Baumgart J et al (2013) Sexual dysfunction in women on adjuvant endocrine therapy after breast cancer. Menopause 20(2):162\u2013168","journal-title":"Menopause"},{"issue":"1","key":"8170_CR32","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s10549-019-05294-w","volume":"177","author":"T Helland","year":"2019","unstructured":"Helland T et al (2019) Drug monitoring of tamoxifen metabolites predicts vaginal dryness and verifies a low discontinuation rate from the Norwegian Prescription Database. Breast Cancer Res Treat 177(1):185\u2013195","journal-title":"Breast Cancer Res Treat"},{"key":"8170_CR33","doi-asserted-by":"publisher","first-page":"320","DOI":"10.2174\/1874312901206010320","volume":"6","author":"M van Laar","year":"2012","unstructured":"van Laar M et al (2012) Pain treatment in arthritis-related pain: beyond NSAIDs. Open Rheumatol J 6:320\u2013330","journal-title":"Open Rheumatol J"},{"issue":"1","key":"8170_CR34","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1212\/WNL.0000000000013038","volume":"98","author":"R Price","year":"2022","unstructured":"Price R et al (2022) Oral and topical treatment of painful diabetic polyneuropathy: practice guideline update summary: report of the AAN Guideline Subcommittee. Neurology 98(1):31\u201343","journal-title":"Neurology"},{"issue":"1","key":"8170_CR35","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1177\/1534735416683807","volume":"17","author":"M Browall","year":"2018","unstructured":"Browall M, Mijwel S, Rundqvist H, Wengstr\u00f6m Y (2018) Physical activity during and after adjuvant treatment for breast cancer: an integrative review of women\u2019s experiences. Integr Cancer Ther 17(1):16\u201330","journal-title":"Integr Cancer Ther"},{"key":"8170_CR36","doi-asserted-by":"crossref","unstructured":"Rogers LQ et al (2023) Physical activity intervention benefits persist months post-intervention: Randomized trial in breast cancer survivors. J Cancer Survivorship p. 1\u201313","DOI":"10.1007\/s11764-022-01329-2"},{"issue":"4","key":"8170_CR37","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1177\/1534735411413270","volume":"11","author":"ML Galantino","year":"2012","unstructured":"Galantino ML et al (2012) Impact of yoga on functional outcomes in breast cancer survivors with aromatase inhibitor\u2013associated arthralgias. Integr Cancer Ther 11(4):313\u2013320","journal-title":"Integr Cancer Ther"},{"issue":"2","key":"8170_CR38","doi-asserted-by":"publisher","first-page":"149","DOI":"10.3322\/caac.21639","volume":"71","author":"NL Stout","year":"2021","unstructured":"Stout NL et al (2021) A systematic review of rehabilitation and exercise recommendations in oncology guidelines. CA Cancer J Clin 71(2):149\u2013175","journal-title":"CA Cancer J Clin"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-08170-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-023-08170-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-08170-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,3]],"date-time":"2024-11-03T06:16:05Z","timestamp":1730614565000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-023-08170-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,27]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["8170"],"URL":"https:\/\/doi.org\/10.1007\/s00520-023-08170-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2497342\/v1","asserted-by":"object"}]},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,27]]},"assertion":[{"value":"20 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All subjects gave their informed consent for inclusion before they participated in the study. The study was conducted in accordance with 45 CFR 46. 109 (f)(1), and the protocol was approved by the Ethics Committee of Thomas Jefferson University IRB using control number 19F.265.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"719"}}